SHU.ai

Shu is a biotechnology company specializing in generative artificial intelligence for accelerated drug discovery. The company leverages its proprietary SHU platform, which integrates deep learning, structural biology, and molecular dynamics to design novel small molecule therapeutics. By focusing on the fundamental physics of protein-ligand interactions, Shu's technology can identify high-affinity binders for traditionally undruggable targets. The company operates a hybrid business model, pursuing an internal pipeline in oncology and infectious diseases while also engaging in strategic collaborations with pharmaceutical partners. Shu aims to transform the drug development paradigm by significantly increasing the success rate of lead optimization and reducing time-to-clinic.